IVIG Treatment for Refractory Immune-Related Adult Epilepsy.

Trial Profile

IVIG Treatment for Refractory Immune-Related Adult Epilepsy.

Phase of Trial: Phase II

Latest Information Update: 29 Oct 2014

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Epilepsy; Partial epilepsies
  • Focus Therapeutic Use
  • Sponsors Baxter Healthcare Corporation
  • Most Recent Events

    • 22 Jan 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 13 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top